De-Escalation Therapy for Human Papillomavirus Negative Disease

Squamous Cell Carcinoma Clinical Trial

— DEPEND  

Official title:

A Phase II Trial of Carboplatin, Paclitaxel, and Nivolumab Induction Therapy Followed by Response-stratified Locoregional Therapy for Patients With Locally Advanced, HPV-negative Head and Neck Cancer. The DEPEND Trial.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03944915
• Other study ID #: IRB19-0162
• Status: Recruiting
• Phase: Phase 2
• Start date: August 26, 2019
• Est. completion date: July 1, 2024

Study information

• Verified date: August 2023
• Source: University of Chicago
• Contact: Everett Vokes, MD
• Phone: 773-702-9306
• Email: evokes[@]medicine.bsd.uchicago.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is looking to see if nivolumab, an immunotherapy drug, given with carboplatin and paclitaxel (2 chemotherapy agents) during induction therapy in advanced stage HPV negative patients can significantly shrink the subject's cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 36
• Est. completion date: July 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have pathologically confirmed locally advanced, non-metastatic, HPV-negative head and neck squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, nasopharynx, larynx, or sinuses.

2. Stage IV disease with the exception of nasopharyngeal tumor-3, node-2 (stage III) based of American Joint Committee on Cancer staging 8th edition

3. If a primary oropharyngeal squamous cell carcinoma is diagnosed, HPV must be ruled out by immunohistochemistry.

4. Availability of =10 unstained 5 micron slides. Patients who cannot fulfill this requirement will need to undergo a new biopsy prior to enrollment on study.

5. Patients must be at least 18 years of age.

6. Measurable disease (either primary site and/or nodal disease) by RECIST criteria.

7. No previous radiation or chemotherapy for a head and neck cancer.

8. No complete surgical resection for a head and neck cancer within 8 weeks of enrollment (although lymph node biopsy including excision of an individual node with presence of residual nodal disease, or surgical biopsy/excision of the tumor with residual measurable disease is acceptable.) No surgical procedures or biopsies will occur after baseline scans are performed and measurable lesions are identified.

9. Eastern Cooperative Oncology Group performance status 0-1

10. Normal Organ Function

1. Leukocytes = 3000/mm3

2. Platelets = 100,000/mm3

3. Absolute neutrophil count = 1,500

4. Hemoglobin = 9.0 gm/dL

5. Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) = 2.5x upper limit of normal

6. Alkaline phosphatase = 2.5x upper limit of normal

7. Albumin > 2.9 gm/dL

8. Total bilirubin = 1.5 mg/dL

9. Creatinine clearance > 45 mL/min, normal within 2 weeks prior to start of treatment (Of note, the standard Cockcroft and Gault formula must be used to calculate creatinine clearance (CrCl) for enrollment or dosing)

11. Patients must sign a study-specific informed consent form prior to study entry. Patients should have the ability to understand and the willingness to sign a written informed consent document.

12. Women of childbearing potential must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of study drug

13. Women must not be breastfeeding

14. Women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 6 months after completing chemoradiation or receiving the last dose of consolidative nivolumab, whichever occurs latest.

15. Men who are sexually active with women of childbearing potential must agree to follow instructions for method(s) of contraception for the duration of treatment with study drug(s) plus 6 months after completing chemoradiation or receiving the last dose of consolidative nivolumab, whichever occurs latest.

Exclusion Criteria:

1. Unequivocal demonstration of distant metastatic disease (M1 disease).

2. Unidentifiable primary site.

3. Inter-current medical illnesses which would impair patient tolerance to therapy or limit survival. This includes but is not limited to ongoing or active infection, immunodeficiency, symptomatic congestive heart failure, pulmonary dysfunction, cardiomyopathy, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance. Patients with clinically stable and/or chronically managed medical illnesses that are not symptomatic and/or are not expected to impact treatment on protocol are still eligible (conditions to be reviewed by the PI to confirm eligibility)

4. Prior surgical therapy other than incisional/excisional biopsy or organ-sparing procedures such as debulking of airway-compromising tumors. Residual measurable tumor is required for enrollment as discussed above.

5. Patients receiving other investigational agents.

6. Diagnosis of immunodeficiency or is receiving systemic steroid therapy in excess of physiologic dose or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

7. Known history of active tuberculosis (Bacillus Tuberculosis infection).

8. Hypersensitivity to nivolumab or any other drug used in this protocol.

9. Prior systemic anti-cancer treatment within the last 8 weeks.

10. Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer or any tumors that are not likely to influence life expectancy in the subsequent 3 years without active treatment.

11. Has active autoimmune disease that has required systemic therapy in the past year (i.e. with steroids or immunosuppressive drugs). Replacement therapy e.g. levothyroxine, insulin, or physiologic corticosteroid doses for adrenal or pituitary insufficiency, etc. are not considered a form of systemic treatment.

12. Has known history of, or any evidence of active, non-infectious pneumonitis.

13. Has a history of HIV.

14. Has known active Hepatitis B or hepatitis C. If eradicated, patient is eligible.

15. Has received a live vaccine within 28 days of planned start of study therapy.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• HNSCC
• HPV-Related Squamous Cell Carcinoma
• Human Papilloma Virus
• Papilloma
• Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck
• Squamous Cell Carcinoma of the Head and Neck

Intervention

Drug:
• Carboplatin
Carboplatin will be given through IV infusions for 30-60 minutes on day 1 of each cycle. Each cycle will last 21 days. There will be 3 cycles.
• Paclitaxel
During Induction Therapy Paclitaxel (100 mg) will be given through IV infusions on days 1, 8 and 15 of each 21 day cycle. There will be 3 cycles. During Radiotherapy, paclitaxel will be given after a dose of radiation by IV infusion for 60 minutes after day 1 of radiotherapy.
• Nivolumab
Nivolumab will be given through IV infusions at 360 mg on day 1 every 21 days for 3 cycles.

Radiation:
• Radiation
Patients will receive 4.5-5 cycles of radiation depending on response. Those with a positive response will receive radiation for 4.5 cycles with a total radiation dose of 66 Gy. Patients with a moderate or no response will receive 5 cycles with a total radiation dose of 70-75 Gy. 2 times a day for days 1-5 followed by a rest period for days 6-13

Drug:
• Hydroxyurea Pill
One dose of hydroxyurea pill by mouth at start of 5-FU infusion during radiotherapy cycle
• 5-fluorouracil
5-FU will be given by IV infusion continuously for 5 days during radiotherapy cycles
• Filgrastim Injection
Filgrastim shot will be given if patient has certain side effects during radiotherapy cycle on days 6-12.
• Cisplatin
Radiotherapy may also be given with a different chemotherapy agent called cisplatin. This is the traditional standard of care chemotherapy regimen. In this case, the radiotherapy will be given once daily for 5 days per week. Cisplatin will be administered via IV once every 21 days for 2 or 3 cycles.

Locations

Country	Name	City	State
United States	University Of Chicago Medicine Comprehensive Cancer Center	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
University of Chicago

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Acute and late toxicity during treatment	Assess long term and late toxicities in all patients receiving induction therapy and risk-adapted chemoradiotherapy after deep response to induction therapy. Acute and late toxicities will be defined using the National Cancer Institute Common Terminology Criteria for Adverse Events. Comparisons will be made using Fisher's exact test. Acute and late toxicity during treatment and at 1 month, 3 months and 1 year post chemoradiation	1 year
Other	Enteral tube dependency	Enteral tube dependency will be defined as continued necessity of any nutrition through enteral tube to maintain weight. The incidence of enteral tube dependency will be described within the safety population and among each radiation treatment. Comparisons will be made using Fisher's exact test.	1 year
Other	Performance Standard Scale for Head and Neck (PSS_HN) Quality of life assessments	Evaluate quality of life in response in patients who receive dose reduced chemoradiotherapy after a deep response to induction therapy. Quality of life assessments will be measured in the safety population. Results will be tabulated and compared using the Fisher's exact test. Overall and domain subset scores of the Performance Standard Scale for Head and Neck (PSS_HN) and Functional Assessment of Cancer Therapy scale Head and Neck quality of life assessments	2 years
Other	Functional Assessment of Cancer Therapy scale Head and Neck Quality of life assessments	Evaluate quality of life in response in patients who receive dose reduced chemoradiotherapy after a deep response to induction therapy. Quality of life assessments will be measured in the safety population. Results will be tabulated and compared using the Fisher's exact test. Overall and domain subset scores of the Performance Standard Scale for Head and Neck (PSS_HN) and Functional Assessment of Cancer Therapy scale Head and Neck quality of life assessments	2 years
Other	Immunohistological biomarkers	Interrogate and understand the immune micro-environment at baseline 2-3 weeks into induction therapy with extensive immunohistological and serum biomarkers. Use biomarker data and efficacy data. These exploratory predictive biomarker analyses will be completed with biomarkers measured in the blood and in tumor samples obtained prior to and near completion of induction therapy. The main tumor biomarkers measured will be PD-L1, tumor mutation burden, and T-cell activated gene signatures. The relationship between measures will be investigated using logistic regression.	2 years
Other	Serum biomarkers	Interrogate and understand the immune micro-environment at baseline 2-3 weeks into induction therapy with extensive immunohistological and serum biomarkers. Use biomarker data and efficacy data. These exploratory predictive biomarker analyses will be completed with biomarkers measured in the blood and in tumor samples obtained prior to and near completion of induction therapy. The main tumor biomarkers measured will be PD-L1, tumor mutation burden, and T-cell activated gene signatures. The relationship between measures will be investigated using logistic regression.	2 years
Primary	Deep Response Rate (DRR)	DRR is 50% or greater response to induction therapy based on RECIST criteria. The objective is to intensify induction chemotherapy with the addition of an immune checkpoint inhibitor aimed at increasing the proportion of patients achieving a deep tumor response in order to subsequently allow risk-adapted definitive chemoradiotherapy in advanced stage HPV negative head and neck squamous cell cancer patients.	2 years
Secondary	Progression Free Survival rate (PFS)	Progression free survival at 24 months after completing chemoradiation. PFS will be defined as the time from registration to the date of the first documented disease progression, clinical progression, or death due to any cause, whichever occurs first.	24 months
Secondary	Overall Survival rate (OS)	Overall survival will be defined as the time between the date of registration and the date of death.	24 months
Secondary	Locoregional control after completing chemoradiation	assess disease control in all patients receiving induction chemoimmunotherapy and compare disease control between radiation arms.	24 months
Secondary	Distant control after completing chemoradiation	Distant control will be defined as the time from registration to the date of the first documented disease progression below the clavicles. Comparison between the two radiation arms will be made.	24 months